MDM2-Dependent Rewiring of Metabolomic and Lipidomic Profiles in Dedifferentiated Liposarcoma Models

• Published in: Cancers Vol. 12; no. 8; p. 2157
• Main Authors: Patt, Andrew, Demoret, Bryce, Stets, Colin, Bill, Kate-Lynn, Smith, Philip, Vijay, Anitha, Patterson, Andrew, Hays, John, Hoang, Mindy, Chen, James L., Mathé, Ewy A.
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 04-08-2020; MDPI
• Subjects: Amino acids; Cell culture; Chemoresistance; Chemotherapy; Lipid metabolism; Lipids; Liposarcoma; MDM2 protein; Mesenchyme; Metabolism; Metabolites; Metabolomics; Molecular modelling; p53 Protein; Peptides; Phenotypes; Physiological aspects; Tumor suppressor genes; Tumors; United States
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers12082157

Dedifferentiated liposarcoma (DDLPS) is an aggressive mesenchymal cancer marked by amplification of MDM2, an inhibitor of the tumor suppressor TP53. DDLPS patients with higher MDM2 amplification have lower chemotherapy sensitivity and worse outcome than patients with lower MDM2 amplification. We hypothesized that MDM2 amplification levels may be associated with changes in DDLPS metabolism. Six patient-derived DDLPS cell line models were subject to comprehensive metabolomic (Metabolon) and lipidomic (SCIEX 5600 TripleTOF-MS) profiling to assess associations with MDM2 amplification and their responses to metabolic perturbations. Comparing metabolomic profiles between MDM2 higher and lower amplification cells yielded a total of 17 differentially abundant metabolites across both panels (FDR < 0.05, log2 fold change < 0.75), including ceramides, glycosylated ceramides, and sphingomyelins. Disruption of lipid metabolism through statin administration resulted in a chemo-sensitive phenotype in MDM2 lower cell lines only, suggesting that lipid metabolism may be a large contributor to the more aggressive nature of MDM2 higher DDLPS tumors. This study is the first to provide comprehensive metabolomic and lipidomic characterization of DDLPS cell lines and provides evidence for MDM2-dependent differential molecular mechanisms that are critical factors in chemoresistance and could thus affect patient outcome.